52 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
Rank Status Study
21 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
22 Recruiting Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Conditions: Sensorineural Hearing Loss;   Cytomegalovirus Infection
Intervention:
23 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis
Conditions: Ulcerative Colitis;   Cytomegalovirus Infections;   Disease Exacerbation
Intervention:
24 Not yet recruiting Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Condition: Cytomegalovirus Infections
Intervention: Biological: IFN-γ positive selected T-cells
25 Recruiting MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Condition: Cytomegalovirus Infections
Interventions: Drug: MK-8228;   Drug: Placebo
26 Recruiting A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
Conditions: Adenovirus Infection;   EBV;   Cytomegalovirus Infections;   Cytokine Capture System®;   Allogenic Disease
Intervention: Biological: IFN-γ positive selected T-cells
27 Recruiting Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Condition: Cytomegalovirus Infections
Interventions: Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
28 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Transplantation Infection;   Epstein-Barr Virus Infections;   Cytomegalovirus Infections
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
29 Recruiting Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus
Conditions: Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
Intervention: Biological: Cytotoxic T Lymphocytes
30 Recruiting Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Condition: Cytomegalovirus Infections
Intervention: Biological: CMV Specific T Cell donor lymphocyte infusion
31 Unknown  Cytomegalovirus (CMV) Infection in Amniotic Fluid
Conditions: Pregnancy Complications;   Cytomegalovirus Infections
Intervention:
32 Recruiting An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Condition: Cytomegalovirus Infections, Transplantation
Intervention:
33 Not yet recruiting Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
Condition: Congenital Cytomegalovirus Infection
Interventions: Drug: Valacyclovir;   Drug: Placebo
34 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
35 Recruiting Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: Standardized test report
36 Unknown  T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
Conditions: Graft Versus Host Disease;   Nonneoplastic Condition
Interventions: Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
37 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
38 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
39 Recruiting Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients
Condition: Cytomegalovirus Disease
Interventions: Other: Preemptive Therapy;   Drug: Prophylaxis with Valganciclovir
40 Not yet recruiting Multi-peptide CMV-MVA Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hodgkin Lymphoma;   Lymphadenopathy;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-52) Show next page of results    Last Page
Indicates status has not been verified in more than two years